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nomogram were determined by concordance index(C-index) 
and calibration curve. 
 
Results: 47% of the patients had extraprostatic extension, 
36% had positive margin, and 20% had Gleason Score 8-10. 
Nomograms were developed for the predicted probabilities of 
having the indications of adjuvant radiation 
therapy(Fig1ABC). The calibration curve for probabilities 
showed good agreement between prediction by nomogram 
and actual observation (Fig 1DEF). The C-index of the 
nomograms for predicting extraprostatic extension disease, 
positive margin, and Gleason Score 8-10 were 0.799, 0.746, 
0.879, respectively. The risk of having one of the indications 
of adjuvant radiation therapy increased with increases in 
predictors except for T stage for predicting Gleason Score 8-
10(p=0.25). 
 
 
Fig.1 nomograms and calibration curves 
 
Conclusion: We produced nomograms that may accurately 
predict the probabilities of having indications for adjuvant 
radiation therapy after RP in men with localized prostate 
cancer, which may contributes to properly selecting initial 
treatment option. 
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Purpose or Objective: Together with surgery, radiotherapy 
(RT) is a cornerstone in the treatment of prostate cancer. 
Despite similar prognostic factors, a wide inter-patient 
variability was observed in tumour response and side effects. 
Many studies have been made to understand molecular 
behaviour of tumours exposed to ionizing radiation. It has 
been hypothesized that single-nucleotide polymorphisms 
(SNPs) impact response and adverse reactions for patients 
(pts) receiving RT. We focused on the analysis of some 
candidate SNPs in pts treated with RT for prostate cancer. 
 
Material and Methods: Between January and September 
2014, 66 pts with prostate cancer underwent RT with radical 
or adjuvant intent. RT was delivered using 4-6 coplanar 10-18 
MV beams at a dose of 70-80 Gy (2.5-2 Gy/fraction). At 
baseline and weekly during treatment, acute gastrointestinal 
(GI) and genitourinary (GU) toxicities were scored by a fixed 
questionnaire. The RTOG toxicity scale served as a basis, but 
additional symptoms were evaluated as well. Genotyping was 
performed from whole blood samples at the beginning of RT. 
DNA was purified with the QIAamp DNA Mini Kit. Assays of 
samples were performed using the “Radiotherapy response” 
kit (Diatech Pharmacogenetics, Italy). Pyrosequencing 
analysis was carried on the PyroMark Q96 ID (Biotage, 
Sweden). Status of candidate SNPs (GSTP1 A313G, RAD51 
G135C, XRCC1 G28152A, XRCC3 A4541G and XRCC3 C18067T) 
was unknown to interviewers and participants. 
 
Results: Treatments were delivered successfully without any 
interruption. Grade 1, Grade 2 and Grade 3 GI toxicities were 
observed in 33%, 12% and 3% of the pts, respectively, during 
the whole period. Grade 1, Grade 2 and Grade 3 GU toxicities 
were seen in 50%, 32% and 15% of the pts. Eight items of GI 
toxicity and six items of GU toxicity were used to calculate, 
for each patient, his own toxicity score. Time of onset of side 
effects was taken into account too. Using R statistical 
program, no significant relation was found between total 
toxicity or precocity of side effects and the mutational status 
of our 5 candidate loci, except for GSTP1 and toxicity. 
Kruskal-Wallis test demonstrated that GSTP1 status (wild-
type, heterozygous and mutant) is a strong predictor of GI 
effects, especially diarrhea (p=0.01), frequency of stools 
(p=0.01), incontinence (p=0.01) and rectal blood loss 
(p=0.02). 
 
Conclusion: Overall, RT is a well tolerated therapy for 
prostate cancer. Five SNPs were analyzed in four genes of 
relevance for RT. GSTP1 showed to be the most important 
SNP regarding GI toxicity to RT in pts treated for prostate 
cancer. Other examined SNPs did not prove to play a 
significant role in this particular subset of pts. Our findings 
require validation in larger replication studies and open to 
future clinical trials. One of the next steps will be evaluate if 
GSPT1 is associated with response to RT too. This would 
permit personalization and optimization of RT for each 
prostate cancer patient. 
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Purpose or Objective: To describe the F-18Fluorocholine 
PET/CT (cPET/TC) activity after biochemical failure in 
localized prostate cancer. To analyze the response to 
cPET/TC-guided salvage therapy. 
 
Material and Methods: N: 80 patients(p) with cPET/TC 
between 2006-2012, 64p at time of biochemical failure. 
At diagnosis 15p T1 (18.5%), 37p T2 (46.4%), 23p T3 (28.8%) 
and 5p T4 (6.3%). N0 (87.5%). Gleason score: 6: 30p (37.6%), 
7: 27p (33.8%),≥ 8: 20p (25.1%), missing: 3p (3.8%). Baseline 
median PSA 9.0 ng/ml. [0.9-114.5]  
Initial treatment: 45p (56.4%) prostatectomy, 13p (16.3%) 
radiotherapy and hormones 2.5 years, 11p (13.8%) 
radiotherapy and hormones 6 months, 7p (8.8%) radiotherapy 
alone and 4p (5%) had hormones alone. 
cPET/TC -guided salvage treatments were: 23 radiotherapy 
(36%), 2 brachytherapy (3.1%), 8 radiotherapy and hormones 
(12.5%), 29 hormones (45.3%), 1 chemotherapy (1.6%) and 1 
radical protatectomy (1.6%). 
 
Results: Median time from diagnosis to cPET/TC failure: 
44.03 months [2.37-126.83]. Median PSA values were 1.69 
ng/ml [0.1-70.6]. 
cPET/TC local failure(LF) occurred in 39p (60.9%), nodal 
failure(NF) in 15p (23.4%) and metastasic failure(MF) in 10p 
(15.6%).  
With a median follow up of 55 m after rescue treatment, 15p 
(23.4%) had biochemical failure again. At 5 years biochemical 
relapse free survival (BRFS) was 65%. Overall survival 5y: 91% 
(median: 119 months). 
BRFS was 59% without LF vs 83% with LF (p 0.26) 
BRFS was 75% without NF vs 30% with NF (p 0.065) 
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BRFS was 77% without MF vs 17% with MF (p 0.001) 
BRFS was: PSA 0.2-1: 83%; 1.1-2: 66%; 2.1-10: 39%; >10.1: 
37%. p: 0.02  
 
Conclusion: cPET/TAC detect initial local and regional 
relapses that can be treated with local radiotherapy with or 
without hormonal therapy with good results. 
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Purpose or Objective: To prospectively evaluate the impact 
of Choline/ PSMA PET-CT imaging on management of patients 
with prostate cancer (PC). 
 
Material and Methods: Fifty patients with high risk or 
recurrent PC received a 11Choline and/or a 68Ga-PSMA-PET-
CT before radiation treatment planning within a prospective 
register study. Main subgroups were identified and only 
patients with a conventional staging before PET-CT were 
evaluated to compare treatment management decisions 
before and after PET-CT with regard to treatment intent, 
target volume (TV) definition, radiation dose and duration of 
androgen deprivation therapy (ADT). 
 
Results: The three main subgroups fulfilling the mentioned 
conditions above were high risk (HR, n=17), recurrence after 
prostatectomy (R, n=12) and R plus salvage radiotherapy 
(RSR, n=7). In HRPC, TNM-changes (n=12/17) led to treatment 
changes (n=14) including TV-changes (n=12). In R, TNM-
changes (n=8/12) resulted in treatment changes (n=8) 
including TV-changes (n=7). In the group after RSR, TNM-
changes (n=6/7) resulted in treatment changes (n=6).  
Management was changed in 82% (HRPC), 66%(R) and 
85%(RSR). Of these groups (n=36) only two patients were 
initially stratified as M1. PET-CT led to downstaging (M0) or 
diagnosed only oligometastatic disease enabling curative 
treatment in both patients. However, in 12 patients initially 
planned for curative treatment detection of N1-disease 
(n=3/9) or newly diagnosed M1-disease (n=9/11) shifted 
treatment allocation to palliative therapy.  
Taken together, curative treatment could be offered to 
initially diagnosed M1-patients (n=2). Since patients with RSR 
were usually in the palliative situation, PET-CT enabled in 
further 28% (2/7) of patients disease localization and curative 
treatment. However, of initially curatively planned patients 
(27/29) with R or HRPC, PET-CT facilitated to avoid 
overtreatment in ~30% (8/27) of patients due to early 
visualization of incurable disease. Main limitation is the 
absence of histological verification. 
 
Conclusion: PET-CT had a pronounced impact on decision 
making and management in this group of patients with high-
risk or recurrent prostate cancer. Therefore we suggest that 
PET-CT should be considered in the work-up in specific 
clinical situations. 
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Purpose or Objective: To evaluate the possible impact of 
positive margins (PM) after surgery for prostate cancer on: I) 
biochemical parameters of recurrence (immediate failure 
rate and the time to development of biochemical recurrence) 
and II) the incidence of macroscopic disease at magnetic 
resonance image (MRI) realized before salvage radiation 
therapy (SRT). 
 
Material and Methods: Data from 101 prostate cancer 
patients treated between 2012-13 was analyzed. Fifty (49.5 
%) had MRI before SRT. PSA failure was defined has a value 
greater than 0.2 ng/ml after 6 weeks after prostatectomy. 
Cases with PSA >0.2 at the first measure 6 weeks after the 
surgery were categorized (no vs yes) and considered 
separately for the analysis of immediate failure. Categorical 
analysis were done using chi-square test. The time to the 
development of biochemical recurrence was presented in 
Kaplan Meier and log-Rank test was used to compare PM vs 
negative margins (MN) group. Mann-Whitney-Wilcoxon test 
was used to compare the PSA means between groups (PM vs 
NM / macroscopic recurrence present vs absent). The 
statistical analysis was done using SPSS V.20. 
 
Results: The basic characteristics of this population were: 
age 66.8 years (median), initial PSA 8.0 ng/ml (median), 
52.6% pT2 and 34.7% pT3. The proportions of each 
pathological risk group were 7%, 42% and 51% (low-risk, 
intermediate risk, high-risk) and 43,6% had PM (n=44). Those 
with PM had an increased chance of immediate PSA failure 
(p=0.004) and an earlier development of biochemical 
recurrence (23.4 months vs 49 months, p = 0.001). The mean 
PSA of the recurrence was 1.4 (+/- 1.7) ng/ml vs 2.6 ng/ml 
(+/- 6.1) (p = 0.839), for NM and PM respectively. Patients 
with macroscopic recurrence had a greater pre-SRT PSA: 3.5 
(+/- 1.7) vs 0.8 (+/- 0.7) ng/ml. The incidence of biochemical 
recurrence with prostatic nodule in the MRI was not 
influenced by margin status (p=0.108) and marginally not 
influenced by pathological status (low or intermediate risk vs 
high risk) (p=0.062). 
 
Conclusion: PM patients have had an earlier development of 
biochemical recurrence but our series did not find a 
significant impact of margin status on the incidence of nodule 
on prostatic bed. A possible delay in the detection of the 
recurrence in margin negative patients should be evaluated 
in next studies. 
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Purpose or Objective: Recent evidences has fostered the 
emergence of Stereotactic Body Radiation Therapy (SBRT) as 
a promising treatment modality for the management of 
localized prostate cancer. In fact, given the low alpha/beta 
ratio of prostate cancer, the delivery of very high radiation 
doses in few fractions, may even improve the therapeutic 
ratio in the treatment of this disease. This phase II study was 
aimed to evaluate the efficacy and toxicity of SBRT in a 
series of patients with low or intermediate risk prostate 
cancer. 
 
Material and Methods: Biopsy confirmed prostate cancer 
patients were enrolled in this phase II trial, provided that 
they had the following characteristics: iPSA < 20 ng/ml, 
Gleason Score < 7, IPSS < 7. The treatment schedule was 35 
Gy in 5 fractions, delivered every other day with VMAT 
technology in FFF modality. Toxicity was recorded according 
